GIULIA RADICE

PhD Graduate

PhD program:: XXXV



Thesis title: Long-term in vivo host immune modulation following CD19-CAR-T cell therapy in diffuse large B-cell lymphoma and B-lineage ALL patients

Chimeric antigen receptor (CAR)-T cells represent a potentially curative strategy for patients with advanced relapsed or refractory (R/R) B-cell malignancies. However, little is known about the in vivo effects of this treatment on the patients' immune lymphocyte populations. In this study, we investigated the effects of Axi-cel and Tisa-cel administration in the control of R/R diffuse large B-cell lymphoma (DLBCL) and B-lineage acute lymphoblastic leukemia (B-ALL), with a primary focus on the immunomodulatory changes induced over time on the host immune system of treated patients. Despite the short in vivo persistence of CAR+ cells, we could document a constant and significant increase over time of CD3+, CD4+, CD8+ and NK cells, associated with an increased capacity of T lymphocytes to produce IFNγ and TNFα. The results obtained also highlight the fact that different co-receptors endow T cells with different functions: the presence of 4-1BB or CD28 domain affects T cells function and fate and our results suggest that infusion with Tisa-cel product induces a bigger expansion of T lymphocytes compartment, which is also found to be functionally more active in producing immunomodulatory cytokines, compared to Axi-cel. We, furthermore, confirmed the prominent role of plasmatic IL-6 in mediating CRS, but we also emphasized the involvement of plasmatic IL-8 in ICANS pathophysiology. IL-8, moreover, emerged as a new early indicator of clinical response, as high IL-8 levels at T3d resulted associated with partial or absent response evaluated at day 30 and month 3. Taken together, these findings show that CAR-T cells are capable to exert a modulation and activation of host immune system, highlighted the differences induced by different product phenotypes and shed light on the role of IL-6 and IL-8 in adverse events.

Research products

11573/1680679 - 2023 - Long-term host immune modulation following tisagenlecleucel administration in patients with diffuse large b-cell lymphoma and b-lineage acute lymphoblastic leukemia
Guarini, Anna; Radice, Giulia; Peragine, Nadia; Buracchi, Chiara; De Propris, Maria Stefania; Di Rocco, Alice; Di Rocco, Arianna; Chiaretti, Sabina; Moretti, Alex; Napolitano, Sara; Martelli, Maurizio; Balduzzi, Adriana; Gaipa, Giuseppe; Biondi, Andrea; Foà, Robin - 01a Articolo in rivista
paper: CANCERS (Basel: MDPI) pp. 1-13 - issn: 2072-6694 - wos: WOS:000987241600001 (2) - scopus: 2-s2.0-85159175129 (3)

11573/1617152 - 2021 - Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab
Puzzolo, M. C.; Radice, G.; Peragine, N.; De Propris, M. S.; Mariglia, P.; Vignetti, M.; Vitale, A.; Bassan, R.; Annunziata, M.; Gaidano, G.; Rambaldi, A.; Chiaretti, S.; Guarini, A.; Foa, R. - 01f Lettera, Nota
paper: BLOOD (New York: Elsevier Inc. [Washington DC etc.]: American Society of Hematology) pp. 2290-2293 - issn: 0006-4971 - wos: WOS:000730824000016 (4) - scopus: 2-s2.0-85120354613 (6)

11573/1416924 - 2019 - Axitinib exposure triggers endothelial cells senescence through ROS accumulation and ATM activation
Mongiardi, M. P.; Radice, G.; Piras, M.; Stagni, V.; Pacioni, S.; Re, A.; Putti, S.; Ferre, F.; Farsetti, A.; Pallini, R.; Barila, D.; Levi, A.; Falchetti, M. L. - 01a Articolo in rivista
paper: ONCOGENE (Macmillan Magazines Limited:Porters South Crinian Street, London N1 9XW United Kingdom:011 44 207 8334000, 011 44 171 8434982, Fax: 011 44 207 812358) pp. 5413-5424 - issn: 0950-9232 - wos: WOS:000473842500006 (32) - scopus: 2-s2.0-85064081474 (36)

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma